

Nutrition in Paediatric Inflammatory Bowel Disease:

A Position Paper on Behalf of The Porto IBD Group of ESPGHAN

Erasmus Miele¹, Raanan Shamir², Marina Aloi³, Amit Assa², Christian Braegger⁴, Jiri Bronsky⁵, Lissy de Ridder⁶, Johanna C. Escher⁶, Iva Hojsak⁷, Sanja Kolaček⁷, Sibylle Koletzko⁸, Arie Levine⁹, Paolo Lionetti¹⁰, Massimo Martinelli¹, Frank Ruemmele¹¹, Richard K. Russell¹², Rotem Sigall Boneh⁹, Johan van Limbergen¹³, Gigi Veereman¹⁴, Annamaria Staiano¹.

1. Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II";
2. Institute for Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel;
3. Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy;
4. Division of Gastroenterology and Nutrition, University Children's Hospital Zurich, Zurich, Switzerland
5. Gastroenterology and Nutrition Unit, Department of Paediatrics, 2nd Faculty of Medicine, Charles, University and Motol University Hospital, Prague, Czech Republic

6. Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands;
7. Department of Gastroenterology, Children Hospital Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia;
8. Dr. von Hauner Children's Hospital, Ludwig Maximilians University Munich, Germany;
9. Wolfson Medical Center, Sackler School of Medicine, Tel-Aviv, Israel;
10. Meyer Children Hospital, University of Florence, Florence, Italy;
11. Université Sorbonne Paris Cité, Université Paris Descartes, and Assistance publique-hôpitaux de Paris, Hôpital Necker-Enfants malades, Service de gastroentérologie pédiatrique, Paris, France;
12. Department of Paediatric Gastroenterology, The Royal Hospital for Children, Glasgow, Scotland;
13. Department of Pediatrics, Division of Pediatric Gastroenterology & Nutrition, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada;
14. Department of Paediatric Gastroenterology and Nutrition, University Hospital Brussels, Free University Brussels, Belgium.

Corresponding Author: Annamaria Staiano, MD

Department of Transitional Medical Science,

Section of Pediatrics

Via S. Pansini, 5

80131 Naples, Italy Phone & Fax: .39.(0)81.7462679

E-mail: staiano@unina.it

Competing interests statement: *Erasmus Miele* received grant/research support from Valeas, served member of advisory board for Abbvie and as a speaker for the following companies: Angelini, Bioprojet, Ferring, Humana, Milte, Takeda; *Raanan Shamir* received grant/research support from Abbott and Enzymotec, served as member of advisory board for Danone Nutrition Institute, served as a speaker for Abbott, Enzymotec, Nestle Nutrition Institute, Nutricia and served as a consultant for Enzymotec, NGS and Nutrinia; *Marina Aloi* served as a member of advisory board and as a speaker for Abbvie; *Amit Assa* received grant/research support from Abbvie, Janssen and Rafa and served as a speaker for Abbvie; *Jiri Bronsky* served as member of advisory board for MSD and Nutricia, served as a speaker for Nutricia, Nestle, Abbvie, MSD and Biocodex; *Lissy de Ridder* received grant/research support from Pfizer, served as a member of advisory board for Shire and Abbvie, and served as a speaker for Mundipharma and Pfizer; *Johanna C. Escher* received grant/research supports from MSD and served as member of advisory board for Janssen and Abbvie; *Iva Hojsak* served as a speaker for BioGaia and Nutricia, and as consultant for Farmas and GM Pharma; *Sanja Kolacek* received grant/research supports from Abbvie, BioGaia, Hospira, Falk, MSD Pharms and Wurth, and served as speaker for Abbott, Abbvie, BioGaia, Danone, Fresenius, MSD, Medis, Nestle, Nutricia and Oktal Pharma; *Sibylle Koletzko* received grant supports from Mead Johnson, served as member of advisory board for Boehringer Ingelheim, Nestle, Danone, Nutricia, Biocodex, Shire, and served as a speaker for Centocor, Danone, Nestle Nutrition Institute and Hipp; *Arie Levine* received grant/research supports from Nestle, served as a member of advisory board for Janssen and as a speaker for Nestle, Janssen and Abbvie; *Paolo Lionetti*

served as member of advisory board for Abbvie and Hospira and served as a speaker for Abbvie, Hospira, Danone and Nestle; *Frank Ruemmele* received grant/research supports from Nestle Nutrition Institute, Abbvie, MSD, Janssen and Centocor, served as a member of advisory board for Nestle Nutrition Institute, Nestle Health Science, Danone, Mead Johnson, Nutricia, Takeda, Celgene, Biogen, Shire, Pfizer, Therakos, and served as a speaker for Abbvie, Danone, Nutricia and Nestle; *Richard K Russell* received grant/research supports from Nestle Health Sciences, served as member of advisory board for Therakos, Abbvie, Vifor, Janssen, Shire, Cow & Gate, Mead Johnson and served as a speaker for Nestle Health Science, Abbvie and Celltrion; *Rotem Sigall Boneh* served as a speaker for Nestle; *Johan van Limbergen* received grant/research supports from Nestle Health Science, Abbvie, Janssen and GSK, served as member of advisory board for Nestle Health Science, Abbvie and Janssen, and served as a speaker for Nestle Health Science, Abbvie and Janssen; *Gigi Veereman* served as member of advisory board for Boehringer, Ingelheim and as a speaker for Mead Johnson; *Annamaria Staiano* received grant/research supports from Aboca, D.M.G. Italy, Milte, Nestle, served as member of advisory board for Sucampo and as a speaker for Aboca, Angelini, Danone, D.M.G. Italy, Menarini, Milte and Valeas.

Abstract

Background and aims: A growing body of evidence supports the need for detailed attention to nutrition and diet in children with IBD. We aimed to define the steps in instituting dietary or nutritional management in light of the current evidence and to offer a useful and practical guide to physicians and dieticians involved in the care of paediatric IBD patients.

Methods: A group of 20 experts in paediatric IBD participated in an iterative consensus process including 2 face-to-face meetings, following an open call to ESPGHAN Porto, IBD Interest and Nutrition Committee. A list of 41 predefined questions was addressed by working subgroups based on a SR of the literature.

Results: A total of 53 formal recommendations and 47 practice points were endorsed with a consensus rate of at least 80% on the following topics: nutritional assessment; nutrition as a primary therapy of paediatric IBD; macronutrients needs; trace Elements, minerals and vitamins; probiotics and prebiotics; specific dietary restrictions; dietary compounds and the risk of IBD.

Conclusions: This position paper represents a useful guide to help the clinicians in the management of nutrition issues in children with IBD.

Keywords: nutrition; IBD; enteral nutrition; Nutritional therapy; paediatrics; Ulcerative colitis; Crohn's Disease

What is known

- A growing body of evidence supports the need for detailed attention to nutrition and diet in children with IBD;
- Despite the increasingly recognized importance of the issue, no specific paediatric dietary guidelines has been published to date.

What is new

- We provide clear recommendations to better define the steps in instituting nutritional management in light of the current evidence;
- This position paper represents a useful practical guide to help physicians and dieticians involved in the care of paediatric IBD patients.

ACCEPTED

Exclusive Enteral Nutrition

What is the efficacy of EEN for the induction of remission of Paediatric CD?

Statement:

- EEN has the same efficacy as oral steroids in the induction of remission of children with active luminal CD (EL 1).
- EEN may be re-used during the course of disease in case of relapse (EL 2).

Although no placebo-controlled randomized controlled trial (RCT) of EEN have been conducted, several RCTs summarized in 3 different meta-analyses, established the efficacy of EEN for the induction of remission in children with CD (177-179). As stated in the most recent guidelines on the therapeutic management of paediatric CD (45), the overall combined remission rate for EEN is 73% (relative risk (RR) 0.95, 95% confidence interval (CI) 0.67–1.34 (178) and RR 0.97, 95% CI 0.7–1.4 (179)). After the publication of the last meta-analysis, 1 RCT and some other prospective studies were published replicating the previous results (180-183). The overall conclusion is that EEN has the same efficacy in the induction of remission as corticosteroids. Recently, the efficacy of EEN has been confirmed in comparison to biological therapy. Lee et al. enrolled 90 consecutive children with an active CD in a prospective study. Patients received EEN, Infliximab or Partial Enteral Nutrition (PEN) as therapy for induction of remission (184). Clinical response was achieved in 88% of children treated with EEN, 84% of those receiving biological therapy and 64% in children undergoing PEN (184).

In conclusion, considering all the benefits of EEN and taking into account the side effects of steroids, EEN should be considered as the first line therapy to induce remission in paediatric luminal CD (45).

Few retrospective studies evaluated the efficacy of a second course of EEN as induction therapy during the course of the disease. Remission rates ranged from 58.3% to 80% (185-188). In the most recent retrospective study including 52 children, Frivolt et al. reported a 92% of remission rate after the first cycle of EEN and 77% after a second cycle of EEN; although a second cycle was used in only 26 children (188). These data confirm that if the compliance of the patients is maintained, EEN may be successfully reused during the subsequent course of the disease for future relapses.

Type of formula and delivery mode

Statement:

- The use of standard polymeric formula, with a moderate fat content, is recommended unless other conditions are present (e.g. cow's milk protein allergy) (EL 1).

Practice Points:

- There is no evidence that the dietary source of proteins affects the efficacy of EEN.
- Initially the formula should be administered orally. A nasogastric tube may be used when there is failure to achieve adequate oral intake.

The source of proteins seems not to affect the efficacy of EEN. Indeed, numerous studies have compared the efficacies of different types (elemental, semi-elemental, oligomeric or polymeric diets) of enteral formulas in the management of active CD with no significant results (189-191). This was further confirmed by a Cochrane meta-analysis of 10 trials showing no statistically significant difference between patients treated with elemental and non-elemental diet (192). Therefore, unless cow's milk protein allergy (CMPA) coexists, polymeric formula should be preferred considering the better palatability and the lower costs (193). Given the pro-

inflammatory properties of some lipids, fats' composition of formulas has been postulated as one of the possible mechanism to explain EEN efficacy. Although, no studies have been published in paediatrics, 2 adults' trials demonstrated no differences when increasing medium chain triglycerides (MCT) (194) or monounsaturated fatty acids (MUFA) content in the formulas (195). Similarly, a sub analysis of a Cochrane demonstrated no differences in induction of remission of CD between low fat and high fat formulas (48). Finally, the addition of metabolites with anti-inflammatory properties such as glutamine (68) or omega-3 (117, 118) has not given positive results and should not be recommended.

To date, few formulas with the adequate caloric intake are available and successfully used for delivering EEN in children. However, no comparison study in terms of effectiveness has been performed so far.

No differences in term of efficacy have been observed between oral EEN and continuous administration through a nasogastric tube (182). Considering that the use of a nasogastric tube may decrease the improvement of quality of life achieved with EEN (196), oral feeds should be preferred. A nasogastric tube should be positioned if adequate caloric intake could not be achieved orally (45).

Duration and reintroduction of foods

Statement:

- EEN is recommended for a period of at least 8 weeks (EL 1).

Practice points:

- There is still insufficient evidence to recommend a standard food reintroduction scheme.

In the absence of evidence we suggest a gradual reintroduction of the foods, with a concomitant reduction of the formula over a 2–3 week period.

There is no evidence regarding the precise duration of EEN. Duration of EEN in clinical studies varied from 2 to 12 weeks, with majority using 6-8 weeks (197). Symptoms usually improve after a few days on EEN and mucosal healing was demonstrated after 8 weeks (198). In accordance with the last CD guidelines we suggest that EEN induction therapy should last at least 6 weeks (45).

There is no evidence to guide reintroduction of normal food after the EEN. Recently, Faiman et al. conducted a retrospective study comparing a standard food reintroduction over 5 weeks versus a rapid reintroduction over 3 days (199). No significant differences were observed in terms of relapse rate and maintenance of remission over 1 year. The authors concluded that due to the better tolerability, a rapid reintroduction should be preferred (199). However, this study suffers several limiting factors; it was retrospective and had very high drop-out (20 out of 31 children with slow introduction and 19 out of 33 were included in the analysis). In the absence of more solid evidences, a gradual food reintroduction with concomitant decrease of formula volume over a 2–3 week period, as suggested in CD guidelines (45), should still be the preferred approach.

Location and behaviour of disease

Statement:

- EEN should be recommended in all cases of active luminal disease irrespective of the GI tract location (EL 2).

Practice points:

- There is insufficient evidence to recommend EEN for isolated oral or perianal disease and for extra-intestinal manifestations.

Opposing data exist regarding the efficacy of EEN and CD disease location. Previous studies (198, 200) suggested a better efficacy of EEN in patients with ileal involvement compared to isolated colonic disease. However, more recent data demonstrated no significant differences between isolated colonic disease and small bowel CD (182, 185). Particularly, in the retrospective study from Rubio et al. which included 106 CD patients, no significant difference was observed regarding location of disease (182). Conversely, another retrospective analysis including 114 children reported that individuals with isolated terminal ileal disease (n=4) had lower remission rates than other locations (p=0.02) (181). In the absence of better scientific evidence, these data support the conclusions of the Cochrane meta-analysis, which suggested the use of EEN in all paediatric CD patients with luminal disease, irrespective of the disease location (177).

To date there are no data to support the use of EEN in patients with isolated extraintestinal manifestations or oral disease. Efficacy of EEN for active perianal disease was reported only in a small case series (201).

Side effects**Practice points:**

- Clinicians should be aware of the risk of refeeding syndrome in severely malnourished children.

- Other possible side effects include: nausea/vomiting, diarrhoea, abdominal discomfort, bloating.

EEN is associated with minimal and temporary side effects. Most common reported are nausea, diarrhoea, constipation, abdominal pain and bloating (202). Borrelli et al. reported that 4 out of 17 patients (23.5%) had mild gastrointestinal side effects (203). The only severe reported adverse event was refeeding syndrome. Refeeding syndrome is defined as a potentially fatal metabolic complication causing shifts in fluids and electrolytes (especially hypophosphatemia) that may occur in severely malnourished patients after the start of refeeding (204). Refeeding syndrome has been described in 3 case reports in very malnourished CD children (205, 206). Therefore, the awareness of a clinician for this life-threatening complication is essential, since the risk of refeeding syndrome can be dramatically decreased by a slow increase of EEN (volume and concentration) over several days, starting with reduced caloric intake [last known intake or 50-75% of the resting energy expenditure (REE)] and advancing only when there are no significant electrolyte abnormalities.

What is the efficacy of EEN for the maintenance of remission of Paediatric Crohn's disease?

Statement:

- There is no evidence for using EEN as a maintenance therapy (EL 4).

Practice Point:

- Due to the highly demanding adherence, EEN should not be considered as an option for long-term maintenance therapy.

No study has evaluated the role of EEN for the maintenance of remission in children with CD. Due to the low compliance of patients after the induction cycle, we do not recommend EEN for the maintenance of remission in children with CD.

What is the efficacy of EEN for the induction and maintenance of remission of Paediatric Ulcerative Colitis?

Statement:

- EEN is not efficacious in the induction and maintenance of remission of paediatric UC (EL 4).

What is the efficacy of EEN on mucosal healing of paediatric Crohn's disease?

Statement:

- EEN promotes mucosal healing (EL 2).
- EEN also promotes transmural healing in a proportion of patients.

Effect of EEN on mucosal healing was investigated by 7 studies (182, 196, 198, 203, 207-209) where endoscopy was performed 8 or 10 weeks after initiation of EEN. All studies found improvement in mucosal inflammation and complete mucosal healing was found in 19-87% of patients. Two studies, one open label RCT (203) and other retrospective study (209) compared mucosal healing between children treated with corticosteroids and with EEN. Both studies found significantly higher rate of mucosal improvement in EEN group (42% vs. 87% and 0 vs.19%). Furthermore, there is evidence that early endoscopic response is associated with reduced relapses, hospitalization and need for anti-TNF treatment at 1 year of follow-up (208). In 3 out of 14 (21 %) children EEN was even able to induce complete transmural remission of ileal CD (208).

What are the long-term outcomes of EEN?

Statement

- EEN improves nutritional status (EL 2) and QoL (EL 3).
- There is insufficient evidence at present to show EEN improves long term bone health (EL 4)

a) Remission duration

Remission duration after EEN is not well determined. Overall 11 studies (180, 186-188, 193, 198, 199, 209-212) reported relapse rate in the longer period of time (10 months to 7 years). Relapse rate ranged from 42%-67% in the first year (188, 193, 199, 210, 212) and 58%-68% at 24 months (180, 187, 212). Median time to first relapse ranged from 6.5 to 12.7 months (186-188). Duration of remission after induction with EEN vs. corticosteroids was assessed by 3 studies and results were contradictory; Thomas et al. found shorter remission duration after EEN (211), but two more recent studies found longer duration of remission if EEN was used as a first line induction therapy (209, 210). Furthermore, although it did not report difference in remission duration after EEN or corticosteroids, one study reported protection against relapses in EEN group during the 24 months period (212). These results, however, should be interpreted with caution due to their retrospective nature and high possibility of other confounding factors.

b) Growth and bone health

All studies investigating weight change during EEN treatment reported positive effect of EEN on weight. Three studies showed an increase in lean body mass (53, 213, 214). Results on height increase are conflicting. Some studies reported height velocity increased immediately after the EEN treatment (203, 208, 209, 215). Furthermore, there

is no agreement on long term results; retrospective studies with no comparative cohort found no significant long term improvement in height Z score (186-188); studies which compared EEN and corticosteroids found conflicting results: 2 studies (211, 216) found better growth rate if EEN was used as a primary induction therapy and one showed no difference (217).

The influence of EEN on bone health has been investigated by 3 studies (214, 217, 218). Werkstetter et al. (214) prospectively evaluated data on bone quality using peripheral quantitative computed tomography (pQCT) and found improved bone metabolism within 3 months of starting EEN with no further normalization afterwards (one year of follow up). EEN therapy also normalized markers of bone turnover 8 weeks after EEN introduction (218). After a follow up of one year EEN group had a non-significant improvement in bone mineral density (BMD) assessed by DXA (217).

c) Quality of life (QoL)

Two studies evaluated QoL after the treatment with EEN both showing improvement in QoL scores after EEN (184, 196). Additionally, patients who received EEN comparing to partial EN and antiTNF therapy had similar improvement in QoL scores (determined by IMPACT score) (184).

Partial Enteral Nutrition

Definition

Partial enteral nutrition (PEN) is defined as providing subjects with a nutritionally balanced liquid formula while continuing to eat an unrestricted or exclusion diet.

What is the efficacy of PEN for the induction of remission of Paediatric Crohn's disease (CD)?

Statement:

- PEN alone should not be used for induction of remission (EL 2)

Practice points:

- PEN in isolation is not efficacious to induce remission in the majority of patients.
- Supplementation with a standard polymeric formula, in addition to conventional induction treatment may be considered.

Johnson et al showed in a RCT the superiority of exclusive enteral nutrition (EEN) over PEN in clinical remission rates defined using the Paediatric Crohn's disease activity index (PCDAI) as the primary outcome measure at 6 weeks (10/24 [42%] vs.4/26 [15%], respectively, $p = 0.03$). In this study, PEN provided an average of 47% of total energy requirements (range 39–58%). (219). Additionally, a recent prospective study of children initiating PEN, EEN, or anti-TNF therapy for active CD, confirmed that each therapy improved symptoms, but EEN and anti-TNF therapies were significantly superior to PEN providing between 80-90% of estimated calories needed for inducing mucosal healing (184). In a retrospective cohort of 28 children with CD, supplementation with polymeric formula, plus conventional treatment, was associated with a decrease in PCDAI whereas children who were not on supplementation did not (220). Gupta et al administered formula overnight to deliver 80-90% of overall needs with the remaining 10% to 20% of their caloric needs came from an unrestricted diet of small meals or snacks during the day. This was effective for the induction of remission in paediatric patients with CD (221). More recently, Sigall-Boneh et al proposed a dietary intervention in mild-to moderate CD, based on 50% PEN and a structured exclusion diet which led to remission in 70% of children. (222).

What is the efficacy of PEN for the maintenance of remission of Paediatric CD?

Statement:

- PEN is a treatment option to maintain remission in selected patients with mild disease and low risk of relapse (EL 4).

What is the optimal daily amount and recommended duration of PEN for the maintenance of remission of Paediatric CD?

- The optimal daily amount and the duration of partial enteral nutrition that needs to be consumed to be effective are unknown (EL 4)

Practice points:

- A long or short-term PEN course, in addition to unrestricted normal or specific food diet may be offered in order to prolong the period of remission in patients who are on no other maintenance treatment for Crohn's disease.

Long-term enteral nutritional supplementation, in addition to unrestricted normal or specific food diet, such as low fat diet; may prolong the period of remission and reduce relapse rates in patients with CD. There is limited research evidence relating to maintenance EN as a treatment for paediatric CD patients, with many of the best studies being performed in adults (223). Yamamoto et al performed a systematic review in adult CD, including 10 studies: one RCT, three prospective non-randomized trials and six retrospective studies. The clinical remission rate was significantly higher in patients receiving PEN in all seven studies comparing PEN to non-supplementation (223). Additionally, in two studies, PEN showed reduction in endoscopic

disease activity. There are a smaller number of paediatric studies. Wilschanski et al showed retrospectively that providing PEN (nocturnal nasogastric supplements), without restriction of normal diet, after successful treatment with EEN, was associated with prolongation of remission and improved linear growth. (224). Duncan et al. Demonstrated that a sub group of patients can successfully continue PEN supplements post induction of remission with EEN as an effective maintenance treatment and had 1 year remission rates matching thiopurines. PEN therefore seems a useful strategy in a sub group of patients especially in those who are not commencing azathioprine or similar maintenance treatments (225). In contrast to the previous studies suggesting the efficacy of PEN, Knight et al reported that the intake of maintenance enteral feeding was not associated with significantly decreased relapse rate (186).

In adult studies investigating the impact of the quantity of enteral formula on clinical remission, higher amounts of enteral formula (35-50%) were associated with higher remission rates. (226, 227). In children the proportion of PEN varies between studies. It is clear that further studies are needed to find appropriate amount, duration, timing of PEN (186).

PROBIOTICS AND PREBIOTICS IN IBD

What is the clinical efficacy and safety of probiotics, when compared to no treatment, placebo, pharmacological treatment or alternative non-pharmacological treatment in the induction and maintenance of remission of paediatric UC and CD?

Statements:

- There is limited evidence in favour of using VSL#3 or *L. reuteri* ATCC 55730 as adjuvant to standard therapy for induction of remission in mild to moderate paediatric UC (EL 2)
- There is evidence in favour of using VSL#3 or *E.coli* Nissle as an alternative to 5-ASA therapy in maintenance of remission in mild to moderate paediatric UC especially in mesalazine intolerance (EL 2)
- VSL#3 has shown efficacy for maintaining antibiotic-induced remission in pouchitis and for preventing it in adults (adult EL 2; paediatric EL 5)
- We do not recommend the use of probiotics in the induction or in the maintenance of remission of paediatric CD (EL 2).

Practice points:

- Probiotics should be used with caution in patients with central venous catheter or in immunocompromised patients.
- Results from clinical trials are strain-specific and should not be extrapolated to other bacterial strains.

High quality studies on the effect of probiotics in paediatric IBD are limited, with only three RCTs two in UC (228, 229) and one in CD (230). Some extrapolations can be made from adult data (231-242) but these have limited applicability in the paediatric population.

Ulcerative colitis

Oliva et al. showed an effect on decrease of both endoscopic (Mayo score) and histological score during 8 weeks of follow-up in group of paediatric patients treated by rectal enema containing *L. reuteri* ATCC 55730 in addition to mesalazine treatment, but not in placebo arm in mild to moderate active distal paediatric UC (229). Miele et al. has shown VSL#3 to be superior to placebo in both induction and maintenance of remission (1 year follow-up) when added to standard treatment in paediatric newly diagnosed UC (228).

An open label study of VSL#3 in induction of remission in children with mild to moderate active UC (243) and another small study on *E.coli Nissle* showing efficacy comparable to 5-ASA in maintenance of remission in paediatric UC (not an RCT) (244) were excluded.

In adults, neither ECCO (232) nor Cochrane review (235) recommend probiotics for induction of remission of mild-to-moderately active UC, despite some studies showing some effect of VSL#3 (228, 245-248). There are no relevant data on probiotics in treatment of acute severe colitis (249).

Based on several RCTs and in accordance with systematic reviews (236, 250), ECCO recommend *E coli Nissle* as an effective alternative to 5-ASA for maintenance therapy in adult UC (232).

Current paediatric UC guidelines (251) conclude in accordance with the Cochrane review (237) that there is insufficient evidence to recommend routine use of probiotics for induction or maintenance of remission in paediatric ambulatory UC patients. However, some probiotics (VSL#3, *E.coli Nissle*) may be considered in children with mild UC intolerant to 5-ASA, or as an adjuvant therapy in those with mild residual activity despite standard therapy. Therapy with VSL#3 has also shown efficacy for maintaining antibiotic-induced remission and for preventing pouchitis in adults (238, 240, 241). Recently, the probiotic mixture VSL#3 has changed

manufacturer and although it contains the same bacteria, its efficacy under the new manufacturing conditions has not yet been scientifically tested in IBD clinical trials.

Crohn's disease

Only one relevant paediatric study was identified showing that *LGG* is not superior to placebo in addition to standard maintenance therapy in paediatric CD (230). Moreover, a meta-analysis has even concluded that *LGG* may increase incidence of relapse in children (252). Also, *Saccharomyces Boulardii* has not shown any efficacy in preventing of relapse in CD adult patients in remission of disease (253). Current paediatric CD guidelines (45) as well as adult ECCO guidelines (233) and Cochrane review (239) are in accordance that there is no significant benefit of probiotics for reducing the risk of relapse compared to standard maintenance therapy.

What is the clinical efficacy and safety of prebiotics, when compared to no treatment, placebo, pharmacological treatment or alternative non-pharmacological treatment in the induction and maintenance of remission of UC and CD?

Statement:

- There is no evidence to the use of prebiotics and/or synbiotics in the induction and in the maintenance of remission of paediatric UC (Adult: EL 2; Paediatric: EL 5) and CD (Adult: EL 2; Paediatric: EL 5).

There are very few data on the effect of prebiotics and synbiotics in paediatric IBD, with no

published clinical trial. The majority of data in adults are limited by the small sample size, short duration and high drop-out rate (254-261). A systematic review of RCT published in 2015, based on major limitations of the studies, including different agents used, sample size and methodological issues, concluded that there is inconclusive evidence of a beneficial role of prebiotics and synbiotics in IBD (262).

What is the clinical efficacy and safety of dietary fibers, when compared to no treatment, placebo, pharmacological treatment or alternative non-pharmacological treatment in the induction and maintenance of remission of UC and CD?

Statements:

- Based on adult studies, fiber supplement intervention may be effective in the management of UC and pouchitis (Adult: EL 2; Paediatric: EL 5).
- There is no evidence to support high-fiber or low-fiber diet in CD (Adult: EL 2; Paediatric: EL 5).

Practice points:

- A possible effect of fiber supplementation associated with standard therapy has been reported in maintenance of remission (psyllium fiber), in active UC (germinated barley fiber) and in maintenance of remission in pouchitis (inulin-enriched oral supplement).
- Fiber restriction should not be recommended in patients with IBD without evidence of stricturing phenotype.

The scientific rationale of using dietary fiber in IBD relates to the production of metabolites (i.e. SCFAs, particularly butyrate) and a beneficial influence on gastrointestinal functions (263). Although no specific paediatric study has been performed, several trials in adults have evaluated the effectiveness and mechanisms of action of fiber in IBD. Based on the published RCT in adults and on 3 systematic reviews, there is limited evidence for the effectiveness of fiber supplementation in active UC and in maintenance of remission in UC and pouchitis (254, 255, 264-275). Data in active UC are conflicting, with few studies reporting a possible effectiveness of fiber supplementation and others no effect on disease outcomes (8,10,14)

Dietary intervention studies didn't show any significant benefit of high versus low-fiber diets in CD (264, 265, 270-272). Based on the current evidences, no dietary fiber restriction should be recommended to patients with IBD without evidence of stricturing phenotype, although monitoring of potential fiber intolerance intake should be performed (263).

SPECIFIC DIETARY RESTRICTIONS FOR PAEDIATRIC IBD

Statement:

- Elimination or restrictive diet in children/adolescents with IBD should not be recommended unless potential benefits outweigh potential risks of the diet (EL 4).

Several diets restricting one or more foods from the diet have been advocated for paediatric and adult patients with IBD to improve symptoms and/or inflammation (274, 276-279). In general, restrictive diets may influence nutritional status, psychological and quality of life. Nutritional restriction may result in unbalanced food intake with deficiency of certain macro- and

micronutrients, which may have negative short and long-term effect, particularly on the growing and developing child. While adults can decide on a specific diet for themselves children depend on the decision and support by their caregivers. Diets should only be considered if they have proven benefit in reducing inflammation, symptoms or both. A list of reported diets is provided in Table 2.

Specific carbohydrate diet (SCD)

Statement:

- A SCD for induction or maintenance of remission in PIBD patients should not be recommended (EL 4).

Practice points

- SCD is an unbalanced diet due restriction of most carbohydrates leading to high protein and high fat intake which has been associated with risk of CD and UC.
- More evidence on the benefit of SCD from RCTs is needed before such a dietary restriction can be recommended to paediatric IBD patients.

The SCD restricts all carbohydrates (starch, polysaccharides and disaccharides) except monosaccharides (glucose, fructose, and galactose). The hypothesis behind is that di- and polysaccharides are poorly absorbed resulting in overgrowth of bacteria and yeast with increased mucus production, small bowel injury and malabsorption. Two retrospective chart reviews of 7 and 26 children with IBD on a SCD showed improvement of symptoms and anthropometry (280, 281). Nine children with CD were prospectively enrolled in a trial of SCD while continuing their normal medication. Lab values, PDCAI and videoendoscopy scores improved, however there was no control group and total energy given was higher compared to the normal diet before

starting SCD(282). Before there is more evidence in favour of a SCD it cannot be recommended in children with IBD.

Lactose free diet (LFD)

Statements

- Symptoms of lactose malabsorption (abdominal pain, bloating, and diarrhoea) overlap with symptoms of active IBD (EL 4).
- A diet with reduced lactose intake with monitoring of symptom improvement may be initiated in children/adolescents with IBD and symptoms suggestive of lactose malabsorption (EL 3).

Practice points

- IBD patients should be counselled not to avoid dairy product, but to reduce high lactose containing products and/or to use lactase treated products or enzyme replacement if lactase deficiency is suspected or intolerance is observed by the patient. If dietary calcium intake is low, calcium supplementation should be considered (283).

Hypersensitivity to lactose (lactose intolerance) results from primary or secondary deficient hydrolysis of lactose in the small intestine by the brush border enzyme lactase phlorizin hydrolase. The population proportion of people who are homozygous for the primary or adult onset of lactase deficiency varies from less than 10% in white Northern Europeans to >80 to 90% in regions of Asia and Africa. Several studies in different populations showed that the primary genetic form of lactose intolerance occurs in the similar frequencies as in the respective control population with the same ethnic background (healthy controls and non-IBD relatives).

Secondary lactose intolerance with lactase deficiency is due to multiple causes resulting in damage of the microvilli of the intestinal mucosa (e.g. inflammation, ulceration, bacterial overgrowth) or reduction of the intestinal surface (resection). A few recent studies in children (284, 285) have shown that IBD patients, particularly with small bowel CD, are more frequently lactose intolerant compared to healthy controls, when assessed by breath testing, symptoms and measurement of brush border enzyme activity. Risk of vitamin D deficiency and low Ca intake with negative impact on bone health has to be taken into account.

Diet low in fermentable oligo-, di- and mono-saccharides and polyol (FODMAPs)

Statement:

- A low FODMAPs diet should not be recommended for induction to remission in children/adolescent with IBD (EL 5).

Practice points

- A strict low FODMAP diet is highly restrictive
- It may improve IBS symptoms for patients without evidence of inflammation. However, it may decrease diversity and induce dysbiosis.
- FODMAP diet may be responsible for nutrient deficiencies (Ca, Folate, Thiamin, Vitamin B6) and cannot be maintained for a long period of time. Dietary counselling is strongly advised.

Mono, Di- and polysaccharides and polyols are poorly absorbed resulting in increased intestinal permeability and increased functional symptoms (abdominal pain, diarrhoea and bloating) in

patients with IBD (286). A few open non-blinded pilot studies improved functional gastrointestinal symptoms in adult IBD patients (287, 288). No paediatric data are available. The diet is low in fiber serving as prebiotics, with potential negative effects on the microbiome and metabolome (289) and a risk of nutrient deficiencies.

Crohn's disease exclusion diet (CDED)

Statement:

- A CDED cannot be recommended as induction therapy due to insufficient evidence (EL 4)

Practice points

- More evidence on the benefit and safety of CDED from RCTs is needed before such a dietary treatment can be recommended to paediatric IBD patients.

The diet is based on exclusion of multiple dietary components (290), and was evaluated for induction of remission in 34 children and 13 adults with mild to moderate CD. The investigators used the diet in conjunction with 50% of caloric intake from one of two polymeric formulas. Remission by week 6 was achieved in 70% of patient, with significant drop in CRP and ESR at both week 6 and week 12, with normalization of CRP in 70% of those entering remission (222). Fifteen patients in remission at week 6, continued dietary restriction and performed a follow up evaluation for mucosal healing, 11/15 achieved complete mucosal healing. This diet is currently being evaluated in a multinational multi-center randomized controlled trial.

Other restrictive diets

Several other diets have been suggested for treatment of active CD or UC including the Paleolithic diet, a vegan diet, a gluten free diet, a diet based on IgG4 testing against foods with excluding foods with high titers (278). In the latter diet the most common foods excluded were milk, beef, pork and egg. The authors reported an improvement in the symptom score compared to a control group on a sham elimination diet, however there was no significant improvement in faecal calprotectin or CRP (291). None of these diets should be recommended to children and adolescents with IBD at present.

7. DIETARY COMPOUNDS AND THE RISK OF IBD

Definition

Dietary compounds with proven effect on the intestinal barrier function directly or indirectly via the modification of the intestinal microbiota potentially implicated in triggering inflammatory or immune-mediated responses leading to IBD

Practice points:

- Avoidance of “westernized” food (high fat, high protein, high sugar, low in fruit and vegetables) identified in epidemiological studies as risk factor for the development of IBD might be considered
- Avoidance of high fat diet (including saturated milk fats) in patients with IBD might be considered

- Avoidance of food or beverages containing large amounts of emulsifiers (i.e. sauces, fast foods, margarines, ice-creams) might be considered

The complex interaction of diet with the host's immune system (directly or indirectly via intestinal microbiota) is a key part in the development of chronic inflammation, the hallmark of IBD. When considering IBD and diet, there are two different aspects: 1) to identify pre-illness dietary patterns/habits that confer a risk to develop IBD in susceptible individuals 2) to identify alimentary factors that impact on the inflammatory state of patients. However, epidemiological or cohort data indicating specific dietary elements as risk factors for developing IBD are often used as indirect evidence to recommend specific nutritional interventions to treat IBD.

Several epidemiological studies discuss a positive correlation between western life style (western diet with high amounts of unsaturated fatty acids, of proteins, a high sugar loads and low vegetables and fruits intake) and the risk of developing IBD (292) (293): A paediatric study confirmed recently a profound imbalance in fat, vegetables and fruits consumption and the development of CD favouring this hypothesis (294). This is in line with adult data from Japan (295, 296) or UK (297) indicating that an increased consumption of trans-unsaturated fatty acids increases the risk of developing UC. However, a prospective cohort study from France failed to show any effect of fat or sugar intake, but the same study identified high protein intake (animal and fish proteins) as positively correlated to the risk of developing IBD (both CD or UC) (298), in keeping with the results of Shoda et al (295) who previously identified a weak positive correlation between high animal and fish protein intake and the risk to develop IBD. Increased dietary fiber intake has been associated with a lower risk of developing CD, but not UC (299). Recently, the results from EPIC study confirmed that high consumption of sugar and soft drinks and low consumption of vegetables are associated with adult UC risk (300).

Important experimental data support the hypothesis that food additives, such as emulsifiers or food thickeners (carboxymethyl cellulose (CMC), carrageenan, polysorbate (P)-60 or P-80, xanthan gum) can have detrimental effects on intestinal homeostasis. In vitro, as well as in vivo analyses with CMC or P60 or P80 revealed that these emulsifiers alter the mucosal epithelial barrier directly or via a change of the intestinal microbiota biodiversity. They can modify the mucosa-adherent biofilm and the conditions for adhesion and translocation of mucosal bacteria. Chassaing et al. (301) recently confirmed in an experimental model that two commonly used emulsifiers CMC and P80 create low-grade inflammation in WT and in genetically susceptible animals severe colitis, completing previous experimental work (302, 303). It is important to note that western diet (fast food and sweet beverages) is rich in emulsifiers. Roberts and colleagues (304) highlighted recently that they observed a clear correlation between annual emulsifier consumption (in food and beverages) and the incidence of IBD, in line with previous studies (293). In the same line, high margarine (rich in emulsifying agents and hydrogenated fats) was identified by independent studies as being positively correlated with the development of UC and in some studies with CD (305, 306).

DISCLAIMER

ESPGHAN is not responsible for the practices of physicians and provides guidelines and position papers as indicators of best practice only. Diagnosis and treatment is at the discretion of physicians.

References

1. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. *World J Gastroenterol* 2009;15:2570-8.
2. Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gastroenterology* 2015;148:1087-106.
3. Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions. *Inflamm Bowel Dis* 2007;13:620-8.
4. Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. *Inflamm Bowel Dis* 2012;18:1961-81.
5. Shah ND, Parian AM, Mullin GE, et al. Oral Diets and Nutrition Support for Inflammatory Bowel Disease: What Is the Evidence? *Nutr Clin Pract* 2015;30:462-73.
6. Sousa Guerreiro C, Cravo M, Costa AR, et al. A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. *Am J Gastroenterol* 2007;102:2551-6.
7. Hartman C, Marderfeld L, Davidson K, et al. Food Intake Adequacy in Children and Adolescents with Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr* 2016;63:437-44.
8. Pons R, Whitten KE, Woodhead H, et al. Dietary intakes of children with Crohn's disease. *Br J Nutr* 2009;102:1052-7.
9. Johnson RK, Yon BA, Hankin JH. Dietary Assessment and Validation. In: Monsen ER VHL, editor. *Research: Successful Approaches*. New York: Elsevier 2008;187-204.
10. Thompson FE, Subar AF. Dietary assessment methodology. In: Coulston AM BC, editor. *Nutrition in the prevention and treatment of disease*. San Diego: Academic Press 2008; 3-39.

11. Shatenstein B, Amre D, Jabbour M, et al. Examining the relative validity of an adult food frequency questionnaire in children and adolescents. *J Pediatr Gastroenterol Nutr* 2010;51:645-52.
12. Rockett HR, Breitenbach M, Frazier AL, et al. Validation of a youth/adolescent food frequency questionnaire. *Prev Med* 1997;26:808-16.
13. Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. *Clin Nutr* 2016;35:557-77.
14. Cezard JP, Touati G, Alberti C, et al. Growth in paediatric Crohn's disease. *Horm Res* 2002;58 Suppl 1:11-5.
15. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. *Gastroenterology* 1988;95:1523-7.
16. Sentongo TA, Semeao EJ, Piccoli DA, et al. Growth, body composition, and nutritional status in children and adolescents with Crohn's disease. *J Pediatr Gastroenterol Nutr* 2000;31:33-40.
17. Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 1993;16:373-80.
18. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. *Gastroenterology* 1993;105:681-91.
19. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with Crohn's disease. *Gut* 1993;34:939-43.
20. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. *Am J Gastroenterol* 2010;105:1893-900.

21. Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. *J Pediatr Gastroenterol Nutr* 2009;48:168-74.
22. Sawczenko A, Ballinger AB, Savage MO, et al. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. *Pediatrics* 2006;118:124-9.
23. Herzog D, Fournier N, Buehr P, et al. Early-onset Crohn's disease is a risk factor for smaller final height. *Eur J Gastroenterol Hepatol* 2014;26:1234-9.
24. Lee JJ, Escher JC, Shuman MJ, et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. *Inflamm Bowel Dis* 2010;16:1669-77.
25. Buderus S, Scholz D, Behrens R, et al. Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry. *Dtsch Arztebl Int* 2015;112:121-7.
26. Malik S, Mason A, Bakhshi A, et al. Growth in children receiving contemporary disease specific therapy for Crohn's disease. *Arch Dis Child*. 2012;97:698-703.
27. Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn's disease. *Nat Rev Gastroenterol Hepatol* 2009;6:513-23.
28. Wine E, Reif SS, Leshinsky-Silver E, et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype, and disease severity. *Pediatrics* 2004;114:1281-6.
29. Lee JJ, Essers JB, Kugathasan S, et al. Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study. *Ann Hum Genet* 2010;74:489-97.

30. Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. *Proc Natl Acad Sci U S A* 2005;102:13260-5.
31. Levine A, Shamir R, Wine E, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. *Am J Gastroenterol* 2005;100:1598-604.
32. Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. *Digestion* 2012;85:308-19.
33. Hyams JS, Moore RE, Leichtner AM, et al. Longitudinal assessment of type I procollagen in children with inflammatory bowel disease subjected to surgery. *J Pediatr Gastroenterol Nutr* 1989;8:68-74.
34. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. *Pediatrics* 2007;119 Suppl 2:S166-74.
35. Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. *J Pediatr Gastroenterol Nutr* 2006;43:42-51.
36. Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. *Inflamm Bowel Dis* 2011;17:2162-8.
37. Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. *J Pediatr* 2007;151:523-7.

38. Poon SS, Asher R, Jackson R, et al. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. *J Crohns Colitis* 2015;9:640-6.
39. Thangarajah D, Hyde MJ, Konteti VK, et al. Systematic review: Body composition in children with inflammatory bowel disease. *Aliment Pharmacol Ther* 2015;42:142-57.
40. Thayu M, Denson LA, Shults J, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. *Gastroenterology* 2010;139:430-8.
41. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. *Pediatr Res* 2003;53:205-10.
42. DeBoer MD, Denson LA. Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains. *J Pediatr* 2013;163:17-22.
43. Mason A, Malik S, McMillan M, et al. A prospective longitudinal study of growth and pubertal progress in adolescents with inflammatory bowel disease. *Horm Res Paediatr* 2015;83:45-54.
44. Hill RJ. Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease. *World J Gastroenterol* 2014;20:3191-7.
45. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J Crohns Colitis* 2014;8:1179-207.
46. Barot LR, Rombeau JL, Feurer ID, et al. Caloric requirements in patients with inflammatory bowel disease. *Ann Surg* 1982;195:214-8.
47. Sasaki M, Johtatsu T, Kurihara M, et al. Energy metabolism in Japanese patients with Crohn's disease. *J Clin Biochem Nutr* 2010;46:68-72.

48. Kushner RF, Schoeller DA. Resting and total energy expenditure in patients with inflammatory bowel disease. *Am J Clin Nutr* 1991;53:161-5.
49. Varille V, Cezard JP, de Lagausie P, et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease. *J Pediatr Gastroenterol Nutr* 1996;23:13-9.
50. Zoli G, Katelaris PH, Garrow J, et al. Increased energy expenditure in growing adolescents with Crohn's disease. *Dig Dis Sci* 1996;41:1754-9.
51. Al-Jaouni R, Hebuterne X, Pouget I, et al. Energy metabolism and substrate oxidation in patients with Crohn's disease. *Nutrition (Burbank, Los Angeles County, Calif)*. 2000;16:173-8.
52. Schneeweiss B, Lochs H, Zauner C, et al. Energy and substrate metabolism in patients with active Crohn's disease. *J Nutr* 1999;129:844-8.
53. Azcue M, Rashid M, Griffiths A, et al. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. *Gut* 1997;41:203-8.
54. Wiskin AE, Wootton SA, Culliford DJ, et al. Impact of disease activity on resting energy expenditure in children with inflammatory bowel disease. *Clin Nutr* 2009;28:652-6.
55. Steiner SJ, Pfefferkorn MD, Fitzgerald JF, et al. Protein and energy metabolism response to the initial dose of infliximab in children with Crohn's disease. *Inflamm Bowel Dis* 2007;13:737-44.
56. Hill RJ, Lewindon PJ, Withers GD, et al. Ability of commonly used prediction equations to predict resting energy expenditure in children with inflammatory bowel disease. *Inflamm Bowel Dis* 2011;17:1587-93.

57. Cormier K, Mager D, Bannister L, et al. Resting energy expenditure in the parenterally fed pediatric population with Crohn's disease. *JPEN J Parenter Enteral Nutr* 2005;29:102-7.
58. Hart JW, Bremner AR, Wootton SA, et al. Measured versus predicted energy expenditure in children with inactive Crohn's disease. *Clin Nutr* 2005;24:1047-55.
59. Wiskin AE, Wootton SA, Cornelius VR, et al. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. *J Pediatr Gastroenterol Nutr* 2012;54:271-6.
60. Steiner SJ, Pfefferkorn MD, Fitzgerald JF, et al. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease. *Pediatr Res* 2008;64:673-6.
61. Diamanti A, Basso MS, Gambarara M, et al. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients. *Int J Colorectal Dis* 2009;24:19-25.
62. Thomas AG, Miller V, Taylor F, et al. Whole body protein turnover in childhood Crohn's disease. *Gut* 1992;33:675-7.
63. Steiner SJ, Noe JD, Denne SC. Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease. *Pediatr Res* 2011;70:484-8.
64. Motil KJ, Grand RJ, Maletskos CJ, et al. The effect of disease, drug, and diet on whole body protein metabolism in adolescents with Crohn disease and growth failure. *J Pediatr* 1982;101:345-51.
65. Martinez-Medina M, Denizot J, Dreux N, et al. Western diet induces dysbiosis with increased *E coli* in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. *Gut* 2014;63:116-24.

66. Suzuki T, Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. *Nutr Metab (Lond)* 2010;7:19.
67. Lev-Tzion R, Griffiths AM, Leder O, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev* 2014:CD006320.
68. Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2007:CD006443.
69. Saltik-Temizel IN, Eren M, Demir H, et al. Bone mineralization in children with inflammatory bowel disease: what is the role of zinc? *Turk J Gastroenterol* 2008;19:234-8.
70. Alkhouri RH, Hashmi H, Baker RD, et al. Vitamin and mineral status in patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2013;56:89-92.
71. Santucci NR, Alkhouri RH, Baker RD, et al. Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2014;59:455-7.
72. Sikora SK, Spady D, Prosser C, El-et al. Trace elements and vitamins at diagnosis in pediatric-onset inflammatory bowel disease. *Clin Pediatr (Phila)* 2011;50:488-92.
73. Vagianos K, Bector S, McConnell J, et al. Nutrition assessment of patients with inflammatory bowel disease. *JPEN J Parenter Enteral Nutr* 2007;31:311-9.
74. Lansdown AB, Mirastschijski U, Stubbs N, et al. S. Zinc in wound healing: theoretical, experimental, and clinical aspects. *Wound Repair Regen* 2007;15:2-16.
75. Geerling BJ, Badart-Smook A, Stockbrugger RW, et al. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. *Eur J Clin Nutr* 2000;54:514-21.

76. Sturniolo GC, Mestriner C, Lecis PE, et al. Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. *Scand J Gastroenterol* 1998;33:644-9.
77. Ringstad J, Kildebo S, Thomassen Y. Serum selenium, copper, and zinc concentrations in Crohn's disease and ulcerative colitis. *Scand J Gastroenterol* 1993;28:605-8.
78. Fernandez-Banares F, Mingorance MD, Esteve M, et al. Serum zinc, copper, and selenium levels in inflammatory bowel disease: effect of total enteral nutrition on trace element status. *Am J Gastroenterol* 1990;85:1584-9.
79. Gentschew L, Bishop KS, Han DY, et al. Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand. *Nutrients* 2012;4:1247-59.
80. Ojuawo A, Keith L. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. *Cent Afr J Med* 2002;48:116-9.
81. Wisikin AE, Fleming BJ, Wootton SA, et al. Anaemia and iron deficiency in children with inflammatory bowel disease. *J Crohns Colitis* 2012;6:687-91.
82. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. *Inflamm Bowel Dis* 2012;18:513-9.
83. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. *J Crohns Colitis* 2015;9:211-22.
84. Pels LP, Van de Vijver E, Waalkens HJ, et al. Slow hematological recovery in children with IBD-associated anemia in cases of "expectant management". *J Pediatr Gastroenterol Nutr* 2010;51:708-13.

85. Lugg S, Beal F, Nightingale P, et al. Iron treatment and inflammatory bowel disease: What happens in real practice? *J Crohns Colitis*. 2014;8:876-80.
86. Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. *Lancet* 1996;348:992-6.
87. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. *Blood* 2011;118:3222-7.
88. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. *Inflamm Bowel Dis* 2006;12:1101-6.
89. Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. *Am J Hematol* 2013;88:97-101.
90. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005;352:1011-23.
91. Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. *Nat Med* 2015;21:221-30.
92. Martinelli M, Strisciuglio C, Alessandrella A, et al. Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease. *J Crohns Colitis* 2016;10:566-74.
93. Mantadakis E. Advances in Pediatric Intravenous Iron Therapy. *Pediatr Blood Cancer* 2016;63:11-6.
94. Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis. *J Crohns Colitis* 2012;6:267-75.

95. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. *Am J Gastroenterol* 2005;100:2503-9.
96. Jaeggi T, Kortman GAM, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. *Gut* 2015;64:731-42.
97. Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. *Gut* 2017;66:863-71.
98. Weiss G. Dietary iron supplementation: a proinflammatory attack on the intestine? *Gut* 2015;64:696-7.
99. Rampton DS, Goodhand JR, Joshi NM, et al. Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial. *J Crohns Colitis* 2017 Jun 1;11(6):706-15.
100. Halpin TC, Jr., Bertino JS, Rothstein FC, Kurczynski EM, Reed MD. Iron-deficiency anemia in childhood inflammatory bowel disease: treatment with intravenous iron-dextran. *J Parenter Enteral Nutr* 1982;6:9-11.
101. Mamula P, Piccoli DA, Peck SN, et al. Total Dose Intravenous Infusion of Iron Dextran for Iron-Deficiency Anemia in Children With Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr* 2002;34:286-90.
102. Laass MW, Straub S, Chainey S, et al. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. *BMC Gastroenterol* 2014;14:184.

103. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. *Am J Gastroenterol* 2008;103:1182-92.
104. Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2013;11:269-77.
105. Evstatiev R, Marteau P, Iqbal T, et al. FERGICor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. *Gastroenterology* 2011;141:846-53.e1-2.
106. Beigel F, Lohr B, Laubender RP, et al. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. *Digestion* 2012;85:47-54.
107. Plantz K, Maxwell E, Mamula P, et al. O-022 Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2016;22 Suppl 1:S8.
108. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. *Scand J Gastroenterol* 2009;44:838-45.
109. Hesso I. Magnesium deficiency in Crohn's disease. *Clin Nutr*. 1990;9:297-8.
110. Galland L. Magnesium and inflammatory bowel disease. *Magnesium*. 1988;7:78-83.
111. Hartman C, Marderfeld L, Davidson K, M, et al. Food Intake Adequacy in Children and Adolescents with Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr* 2016;63:437-44.

112. Filippi J, Al-Jaouni R, Wiroth JB, et al. Nutritional deficiencies in patients with Crohn's disease in remission. *Inflamm Bowel Dis* 2006;12:185-91.
113. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. *Aliment Pharmacol Ther* 1996;10:777-86.
114. Benchimol EI, Ward LM, Gallagher JC, et al. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2007;45:538-45.
115. Schmidt S, Mellstrom D, Norjavaara E, et al. Low bone mineral density in children and adolescents with inflammatory bowel disease: a population-based study from Western Sweden. *Inflamm Bowel Dis* 2009;15:1844-50.
116. Schmidt S, Mellstrom D, Norjavaara E, et al. Longitudinal assessment of bone mineral density in children and adolescents with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2012;55:511-8.
117. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. *Inflamm Bowel Dis* 2007;13:42-50.
118. Laakso S, Valta H, Verkasalo M, et al. Impaired bone health in inflammatory bowel disease: a case-control study in 80 pediatric patients. *Calcif Tissue Int.* 2012;91:121-30.
119. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. *Gastroenterology* 1998;114:902-11.

120. Paganelli M, Albanese C, Borrelli O, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 2007;13:416-23.
121. Lopes LH, Sdepanian VL, Szejnfeld VL, et al. Risk factors for low bone mineral density in children and adolescents with inflammatory bowel disease. *Dig Dis Sci* 2008;53:2746-53.
122. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. *Osteoporos Int* 1994;4:368-81.
123. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int* 2014;25:2359-81.
124. Braegger C, Campoy C, Colomb V, et al. Vitamin D in the healthy European paediatric population. *J Pediatr Gastroenterol Nutr* 2013;56:692-701.
125. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. *Pediatrics* 2008;122:1142-52.
126. Sadeghian M, Saneei P, Siassi F, et al. Vitamin D status in relation to Crohn's disease: Meta-analysis of observational studies. *Nutrition Nutrition*. 2016;32:505-14
127. Torki M, Gholamrezaei A, Mirbagher L, et al. Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases. *Dig Dis Sci* 2015;60:3085-91.
128. Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. *Am J Gastroenterol* 2016;111:712-9.
129. Castro FD, Magalhaes J, Carvalho PB, et al. LOWER LEVELS OF VITAMIN D CORRELATE WITH CLINICAL DISEASE ACTIVITY AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE. *Arq Gastroenterol* 2015;52:260-5

130. Veit LE, Maranda L, Fong J, et al. The vitamin D status in inflammatory bowel disease. *PloS One* 2014;9:e101583.
131. Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. *Pediatrics* 2006;118:1950-61.
132. El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. *Dig Dis Sci* 2011;56:825-9.
133. Levin AD, Wadhera V, Leach ST, et al. Vitamin D deficiency in children with inflammatory bowel disease. *Dig Dis Sci* 2011;56:830-6.
134. Wingate KE, Jacobson K, Issenman R, et al. 25-Hydroxyvitamin D concentrations in children with Crohn's disease supplemented with either 2000 or 400 IU daily for 6 months: a randomized controlled study. *J Pediatr* 2014;164:860-5.
135. Pappa HM, Mitchell PD, Jiang H, et al. Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens. *J Clin Endocrinol Metab* 2014;99:3408-17.
136. Pappa HM, Mitchell PD, Jiang H, et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. *J Clin Endocrinol Metab* 2012;97:2134-42.
137. Simek RZ, Prince J, Syed S, et al. Pilot Study Evaluating Efficacy of 2 Regimens for Hypovitaminosis D Repletion in Pediatric Inflammatory Bowel Disease *J Pediatr Gastroenterol Nutr* 2016;62:252-8.
138. Shepherd D, Day AS, Leach ST, et al. Single High-Dose Oral Vitamin D3 Therapy (Stoss): A Solution to Vitamin D Deficiency in Children With Inflammatory Bowel Disease? *J Pediatr Gastroenterol Nutr* 2015;61:411-4.

139. Siffledeen JS, Fedorak RN, Siminoski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. *Clin Gastroenterol Hepatol* 2005;3:122-32.
140. D'Odorico A, Bortolan S, Cardin R, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. *Scand J Gastroenterol* 2001;36:1289-94.
141. Hengstermann S, Valentini L, Schaper L, et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. *Clin Nutr* 2008;27:571-8.
142. Hashemi J, Asadi J, Amiriani T, et al. Serum vitamins A and E deficiencies in patients with inflammatory bowel disease. *Saud Med J*. 2013;34:432-4.
143. Bousvaros A, Zurakowski D, Duggan C, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. *J Pediatr Gastroenterol Nutr* 1998;26:129-35.
144. Debier C. Vitamin E during pre- and postnatal periods. *Vitam Horm* 2007;76:357-73.
145. Kuroki F, Iida M, Tominaga M, et al. Multiple vitamin status in Crohn's disease. Correlation with disease activity. *Dig Dis Sci* 1993;38:1614-8.
146. Krasinski SD, Russell RM, Furie BC, et al. The prevalence of vitamin K deficiency in chronic gastrointestinal disorders. *Am J Clin Nutr* 1985;41:639-43.
147. Schoon EJ, Muller MC, Vermeer C, et al. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? *Gut* 2001;48:473-7.
148. Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. *Am J Gastroenterol* 2004;99:2178-85.

149. Nowak JK, Grzybowska-Chlebowczyk U, Landowski P, et al. Prevalence and correlates of vitamin K deficiency in children with inflammatory bowel disease. *Sci Rep* 2014;4:4768.
150. Fernandez-Banares F, Abad-Lacruz A, Xiol X, et al. Vitamin status in patients with inflammatory bowel disease. *Am J Gastroenterol* 1989;84:744-8.
151. Hodges P, Gee M, Grace M, et al. Vitamin and iron intake in patients with Crohn's disease. *J Am Diet Assoc* 1984;84:52-8.
152. Urbano AP, Sasaki LY, Dorna MS, et al. Nutritional intake according to injury extent in ulcerative colitis patients. *J Hum Nutr Diet* 2013;26:445-51.
153. Tsiountsioura M, Wong JE, Upton J, et al. Detailed assessment of nutritional status and eating patterns in children with gastrointestinal diseases attending an outpatients clinic and contemporary healthy controls. *Eur J Clin Nutr* 2014;68:700-6.
154. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. *Am J Gastroenterol* 2003;98:112-7.
155. Yakut M, Ustun Y, Kabacam G, et al. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. *Eur J Intern Med.* 2010;21:320-3.
156. Vagianos K, Bernstein CN. Homocysteinemia and B vitamin status among adult patients with inflammatory bowel disease: a one-year prospective follow-up study. *Inflam Bowel Dis* 2012;18:718-24.
157. Bermejo F, Algaba A, Guerra I, et al. Should we monitor vitamin B12 and folate levels in Crohn's disease patients? *Scand J Gastroenterol* 2013;48:1272-7.
158. Nakano E, Taylor CJ, Chada L, McGaw J, Powers HJ. Hyperhomocystinemia in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2003;37:586-90.

159. Heyman MB, Garnett EA, Shaikh N, et al. Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease. *Am J Clin Nutr* 2009;89:545-50.
160. Phelip JM, Ducros V, Faucheron JL, et al Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2008;14:242-8.
161. Lindenbaum J. Drugs and vitamin B12 and folate metabolism. *Curr Concepts Nutr* 1983;12:73-87.
162. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev*. 2013;(5):CD000951.
163. Saibeni S, Bollani S, Losco A, et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. *Dig Liv Dis* 2012;44:123-7.
164. McNulty H, Scott JM. Intake and status of folate and related B-vitamins: considerations and challenges in achieving optimal status. *B J Nutr* 2008;99 Suppl 3:S48-54.
165. Savage DG, Lindenbaum J, Stabler SP, et al. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. *Am J Med* 1994;96:239-46.
166. Battat R, Kopylov U, Szilagyi A, S et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. *Inflamm Bowel Dis* 2014;20:1120-8.
167. Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. *Inflamm Bowel Dis* 2008;14:217-23.

168. Ward MG, Kariyawasam VC, Mogan SB, Patel KV, Pantelidou M, Sobczynska-Malefora A, et al. Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease. *Inflamm Bowel Dis* 2015;21:2839-47.
169. Coull DB, Tait RC, Anderson JH, et al. Vitamin B12 deficiency following restorative proctocolectomy. *Colorectal Dis* 2007;9:562-6.
170. Thompson WG, Wrathell E. The relation between ileal resection and vitamin B12 absorption. *Can J Surg* 1977;20:461-4.
171. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. *Nutrition* 2006;22:1210-3.
172. Stabler SP. Vitamin B12 deficiency. *N Engl J Med* 2013;368:2041-2.
173. Elriz K, Palascak-Juif V, Joly F, et al. Crohn's disease patients with chronic intestinal failure receiving long-term parenteral nutrition: a cross-national adult study. *Aliment Pharmacol Ther* 2011;34:931-40.
174. Abi Nader E, Lambe C, Talbotec C, et al. Outcome of home parenteral nutrition in 251 children over a 14-y period: report of a single center. *Am J Clin Nutr* 2016;103:1327-36.
175. Greenberg GR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. *Gut* 1988;29:1309-15.
176. Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Long-term maintenance of remission by personalized food exclusion diets. *Dig Dis Sci* 1987;32(12 Suppl):100S-7S.
177. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2007: Cd000542.

178. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. *J Pediatr Gastroenterol Nutr* 2000;31:8-15.
179. Dziechciarz P, Horvath A, Shamir R, et al. Meta-analysis: enteral nutrition in active Crohn's disease in children. *Aliment Pharmacol Ther* 2007;26:795-806.
180. Grogan JL, Casson DH, Terry A, et al. Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up. *Inflamm Bowel Dis* 2012;18:246-53.
181. Buchanan E, Gaunt WW, Cardigan T, et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. *Aliment Pharmacol Ther* 2009;30:501-7.
182. Rubio A, Pigneur B, Garnier-Lengline H, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. *Aliment Pharmacol Ther* 2011;33:1332-9.
183. Levine A, Turner D, Pfeffer Gik T, et al. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. *Inflamm Bowel Dis* 2014;20:278-85.
184. Lee D, Baldassano RN, Otley AR, et al. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease. *Inflamm Bowel Dis* 2015;21:1786-93.
185. Day AS, Whitten KE, Lemberg DA, et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. *J Gastroenterol Hepatol* 2006;21:1609-14.

186. Knight C, El-Matary W, Spray C, et al. Long-term outcome of nutritional therapy in paediatric Crohn's disease. *Clin Nutr* 2005;24:775-9.
187. Cameron FL, Gerasimidis K, Papangelou A, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. *Aliment Pharmacol Ther* 2013;37:622-9.
188. Frivolt K, Schwerd T, Werkstetter KJ, et al. Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome. *Aliment Pharmacol Ther* 2014;39:1398-407.
189. Akobeng AK, Miller V, Stanton J, et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. *J Pediatr Gastroenterol Nutr* 2000;30:78-84.
190. Ludvigsson JF, Krantz M, Bodin L, et al. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. *Acta Paediatrica* 2004;93:327-35.
191. Verma S, Brown S, Kirkwood B, et al. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. *Am J Gastroenterol* 2000;95:735-9.
192. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev* 2007:CD005984.
193. Rodrigues AF, Johnson T, Davies P, et al. Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease? *Arch Dis Child* 2007;92:767-70.

194. Sakurai T, Matsui T, Yao T, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. *JPEN J Parenter Enteral Nutr* 2002;26:98-103.
195. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. *Gut* 2002;51:164-8.
196. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. *Aliment Pharmacol Ther* 2004;20:167-72.
197. Whitten KE, Rogers P, Ooi CY, et al. International survey of enteral nutrition protocols used in children with Crohn's disease. *J Dig Dis* 2012;13:107-12.
198. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. *Aliment Pharmacol Ther* 2000;14:281-9.
199. Faiman A, Mutalib M, Moylan A, et al. Standard versus rapid food reintroduction after exclusive enteral nutritional therapy in paediatric Crohn's disease. *Eur J Gastroenterol Hepatol* 2014;26:276-81.
200. Afzal NA, Davies S, Paintin M, et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. *Dig Dis Sci* 2005;50:1471-5.
201. Wong S, Lemberg DA, Day AS. Exclusive enteral nutrition in the management of perianal Crohn's disease in children. *J Dig Dis* 2010;11:185-8.

202. Day AS, Whitten KE, Sidler M, et al. Systematic review: nutritional therapy in paediatric Crohn's disease. *Aliment Pharmacol Ther* 2008;27:293-307.
203. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. *Clin Gastroenterol Hepatol* 2006;4:744-53.
204. Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. *BMJ* 2008;336:1495-8.
205. Afzal NA, Addai S, Fagbemi A, et al. Refeeding syndrome with enteral nutrition in children: a case report, literature review and clinical guidelines. *Clin Nutr* 2002;21:515-20.
206. Akobeng AK, Thomas AG. Refeeding syndrome following exclusive enteral nutritional treatment in Crohn disease. *J Pediatr Gastroenterol Nutr* 2010;51:364-6.
207. Beattie RM, Schiffrin EJ, Donnet-Hughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. *Aliment Pharmacol Ther* 1994;8:609-15.
208. Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. *J Gastroenterol* 2014;49:638-45.
209. Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. *Dig Liv Dis* 2006;38:381-7.
210. Hojsak I, Pavic AM, Misak Z, et al. Risk factors for relapse and surgery rate in children with Crohn's disease. *European journal of pediatrics*. 2014;173(5):617-21.
211. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. *J Pediatr Gastroenterol Nutr* 1993;17(1):75-81.
212. Lambert B, Lemberg DA, Leach ST, et al. Longer-term outcomes of nutritional management of Crohn's disease in children. *Dig Dis Sci* 2012;57:2171-7.

213. Gerasimidis K, Talwar D, Duncan A, et al. Impact of exclusive enteral nutrition on body composition and circulating micronutrients in plasma and erythrocytes of children with active Crohn's disease. *Inflamm Bowel Dis* 2012;18:1672-81.
214. Werkstetter KJ, Schatz SB, Alberer M, et al Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn's disease patients. *Annals of nutrition & metabolism*. 2013;63:10-6.
215. de Bie C, Kindermann A, Escher J. Use of exclusive enteral nutrition in paediatric Crohn's disease in The Netherlands. *J Crohns Colitis* 2013;7:263-70.
216. Grover Z, Lewindon P. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines. *Dig Dis Sci* 2015;60:3069-74.
217. Soo J, Malik BA, Turner JM, et al. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease. *Dig Dis Sci*. 2013;58:3584-91.
218. Whitten KE, Leach ST, Bohane TD, et al. Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. *J Gastroenterol* 2010;45:399-405.
219. Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. *Gut* 2006;55:356-61.
220. Hartman C, Berkowitz D, Weiss B, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. *Isr Med Assoc J* 2008;10:503-7.
221. Gupta K, Noble A, Kachelries KE, et al. A novel enteral nutrition protocol for the treatment of pediatric Crohn's disease. *Inflamm Bowel Dis* 2013;19:1374-8.

222. Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. *Inflamm Bowel Dis* 2014;20:1353-60.
223. Yamamoto T, Nakahigashi M, Umegae S, et al. Enteral nutrition for the maintenance of remission in Crohn's disease: a systematic review. *Eur J Gastroenterol Hepatol* 2010;22:1-8.
224. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. *Gut* 1996;38:543-8.
225. Duncan H, Buchanan E, Cardigan T, et al. A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing! *BMC Gastroenterol* 2014;14:50.
226. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. *Aliment Pharmacol Ther* 2006;24:1333-40.
227. Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. *Dig Liv Dis* 2000;32:769-74.
228. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. *Am J Gastroenterol* 2009;104:437-43.
229. Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of *Lactobacillus reuteri* ATCC 55730 rectal enema in children with active distal ulcerative colitis. *Aliment Pharmacol Ther* 2012;35:327-34.

230. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. *Inflamm Bowel Dis* 2005;11:833-9.
231. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2008:CD006634.
232. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 2012;6:991-1030.
233. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. *J Crohns Colitis* 2010;4:28-62.
234. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn's disease. *Cochrane Database Syst Rev* 2009:CD006873.
235. Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2007:CD005573.
236. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. *J Clin Gastroenterol* 2011;45 Suppl:S139-44.
237. Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2011:CD007443.
238. Oresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. *J Crohns Colitis* 2015;9:4-25.
239. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev* 2006:CD004826.

240. Singh S, Stroud AM, Holubar SD, et al Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Cochrane Database Syst Rev* 2015;CD001176.
241. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. *J Crohns Colitis* 2013;7:1-33.
242. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. *J Crohns Colitis* 2010;4:63-101.
243. Huynh HQ, deBruyn J, Guan L, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. *Inflamm Bowel Dis* 2009;15:760-8.
244. Henker J, Muller S, Laass MW, et al. Probiotic *Escherichia coli* Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. *Z Gastroenterol* 2008;46:874-5.
245. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. *Am J Gastroenterol* 2005;100:1539-46.
246. Guandalini S. Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease. *Expert Rev Clin Immunol* 2010;6:47-54.
247. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clin Gastroenterol Hepatol* 2009;7:1202-9, 9 e1.

248. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol* 2010;105:2218-27.
249. Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. *Am J Gastroenterol* 2011;106:574-88.
250. Michail S, Sylvester F, Fuchs G, et al. Clinical efficacy of probiotics: review of the evidence with focus on children. *J Pediatr Gastroenterol Nutr* 2006;43:550-7.
251. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. *J Pediatr Gastroenterol Nutr* 2012;55:340-61.
252. Shen J, Ran HZ, Yin MH, et al. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. *Intern Med J* 2009;39:103-9.
253. Bourreille A, Cadiot G, Le Dreau G, et al. *Saccharomyces boulardii* does not prevent relapse of Crohn's disease. *Clin Gastroenterol Hepatol* 2013;11:982-7.
254. Faghfoori ZI, Navai L, Shakerhosseini R, et al. . Effects of an oral supplementation of germinated barley foodstuff on serum tumour necrosis factor-alpha, interleukin-6 and -8 in patients with ulcerative colitis. . *Ann Clin Biochem* 2011;48:233-7.
255. Ishikawa H MS, Ohashi Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. *Digestion*. 2011;84:128-33.

256. Benjamin JL HC, Koutsoumpas A, Ng SC, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. *Gut*. 2011;60:923-9.
257. Steed H MG, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. *Aliment Pharmacol Ther*. 2010;32:872-83.
258. Fujimori S, Gudis K, Mitsui K, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. *Nutrition* 2009;25:520-5.
259. Chermesh I, Tamir A, Reshef R, et al. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. *Dig Dis Sci* 2007;52:385-9.
260. Furrle E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. *Gut* 2005;54:242-9.
261. Hafer A, Krämer S, Duncker S, et al. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease. *BMC Gastroenterol* 2007;7:36.
262. Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. *Clin Exp Gastroenterol* 2014;7:473-87.
263. Wedlake L, Slack N, Andreyev HJ, et al. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. *Inflamm Bowel Dis* 2014;20:576-87.

264. Brotherton CS, Taylor AG, Bourguignon C, et al. A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease. *Gastroenterol Nurs* 2014;37:2016-16.
265. Bartel G, Weiss I, Turetschek K, et al. . Ingested matter affects intestinal lesions in Crohn's disease. *Inflamm Bowel Dis* 2008;14:374-82.
266. Seidner DL, Lashner BA, Brzezinski A . An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. *Clin Gastroenterol Hepatol*. 2005;3:358-69.
267. Kanauchi O, Suga T, Tochiwara M et al. . Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. *J Gastroenterol* 2002;37 Suppl 14:67-72.
268. Fernández-Bañares F, Hinojosa J, Sánchez-Lombrana JL, et al. Randomized clinical trial of *Plantago ovata* seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. *Am J Gastroenterol* 1999;94:427-33.
269. Ejderhamn J, Hedenborg G, Strandvik B. Long-term double-blind study on the influence of dietary fibres on faecal bile acid excretion in juvenile ulcerative colitis. *Scand J Clin Lab Invest* 1992;52:697-706.
270. Ritchie JK, Wadsworth J, Lennard-Jones J, et al. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease. *Br Med J (Clin Res Ed)*. 1987;295:517-20
271. Levenstein S PC, Luzi C, D'Ubaldi A. Low residue or normal diet in Crohn's disease: a prospective controlled study in Italian patients. *Gut* 1985;26:989-93.

272. Jones VA, Dickinson RJ, Workman E., et al. Crohn's disease: maintenance of remission by diet. *Lancet* 1985;2:177-80.
273. Liu X, Wu Y, Li F, et al. Dietary fiber intake reduces risk of inflammatory bowel disease: result from a meta-analysis. *Nutr Res* 2015;35:753-8.
274. Charlebois A RG, Bressler B. The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review. *Crit Rev Food Sci Nutr* 2016;56:1370-8.
275. Thies F, Masson LF, Boffetta P, et al. Oats and bowel disease: a systematic literature review. *Br J Nutr* 2014;112:31-43.
276. Penagini F, Dilillo D, Borsani B, et al. Nutrition in Pediatric Inflammatory Bowel Disease: From Etiology to Treatment. A Systematic Review. *Nutrients* 2016;8.
277. Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. *World J Gastroenterol* 2016;22:2179-94.
278. Hou JK, Lee D, Lewis J. Diet and inflammatory bowel disease: review of patient-targeted recommendations. *Clin Gastroenterol Hepatol* 2014;12:1592-600.
279. Ruemmele FM. Role of Diet in Inflammatory Bowel Disease. *Ann Nutr Metab* 2016;68 Suppl 1:33-41.
280. Suskind DL, Wahbeh G, Cohen SA, et al. Patients Perceive Clinical Benefit with the Specific Carbohydrate Diet for Inflammatory Bowel Disease. *Dig Dis Sci* 2016;61:3255-60.
281. Obih C, Wahbeh G, Lee D, et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. *Nutrition* 2016;32:418-25.
282. Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. *J Pediatr Gastroenterol Nutr* 2014;59:516-21.

283. Vernia P, Loizos P, Di Giuseppantonio I, et al. Dietary calcium intake in patients with inflammatory bowel disease. *J Crohns Colitis* 2014;8:312-7.
284. Pawlowska K, Umlawska W, Iwanczak B. Prevalence of Lactose Malabsorption and Lactose Intolerance in Pediatric Patients with Selected Gastrointestinal Diseases. *Adv Clin Exp Med* 2015;24:863-71.
285. Wiecek S, Wos H, Radziejewicz Winnicki I, et al. Disaccharidase activity in children with inflammatory bowel disease. *Turk J Gastroenterol* 2014;25:185-91.
286. Gibson PR, Shepherd SJ. Personal view: food for thought--western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. *Aliment Pharmacol Ther* 2005;21:1399-409.
287. Geary RB, Irving PM, Barrett JS, et al. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. *J Crohns Colitis* 2009;3:8-14.
288. Prince AC, Myers CE, Joyce T, et al. Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2016;22:1129-36.
289. Halmos EP, Christophersen CT, Bird AR, et al. Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn's Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. *Clin Transl Gastroenterol* 2016;7:e164.
290. Pfeffer-Gik T, Levine A. Dietary clues to the pathogenesis of Crohn's disease. *Dig Dis* 2014;32:389-94.
291. Gunasekera V, Mendall MA, Chan D, et al. Treatment of Crohn's Disease with an IgG4-Guided Exclusion Diet: A Randomized Controlled Trial. *Dig Dis Sci* 2016;61:1148-57.

292. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. *Am J Gastroenterol* 2011;106:563-73.
293. Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. *Epidemiology* 1992;3:47-52.
294. Amre DK, D'Souza S, Morgan K, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. *Am J Gastroenterol* 2007;102:2016-25.
295. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. *Am J Clin Nutr* 1996;63:741-5.
296. Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. *Inflamm Bowel Dis* 2005;11:154-63.
297. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. *Gut* 2014;63:776-84
298. Jantchou P, Morois S, Clavel-Chapelon F, et al. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. *Am J Gastroenterol* 2010;105:2195-201.
299. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. *Gastroenterology* 2013;145:970-7.
300. Racine A, Carbonnel F, Chan SS, et al. Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study. *Inflamm Bowel Dis* 2016;22:345-54.

301. Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. *Nature* 2015;519:92-6.
302. Roberts CL, Keita AV, Duncan SH, et al. Translocation of Crohn's disease *Escherichia coli* across M-cells: contrasting effects of soluble plant fibres and emulsifiers. *Gut* 2010;59:1331-9.
303. Nickerson KP, Homer CR, Kessler SP, et al. The dietary polysaccharide maltodextrin promotes *Salmonella* survival and mucosal colonization in mice. *PLoS one* 2014;9:e101789.
304. Roberts CL, Rushworth SL, Richman E, et al. Hypothesis: Increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease. *J Crohns Colitis* 2013;7:338-41.
305. Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease? *Eur J Gastroenterol Hepatol* 2003;15:607-13.
306. Maconi G. Pre-illness changes in dietary habits and diet as a risk factor for inflammatory bowel disease: A case-control study. *World J Gastroenterol* 2010;16:4297.

Table 1. Estimated Energy Requirements

Male and female 4-18 years	% of total calories per day	RDA/AI
Protein	10-30%	Varies on the basis of age and gender
Carbohydrate	45-60%	ND
Fat	40% 6-12 months 35-40% 1-3 yrs 20-25% >4 years	ND

Based on the following European Food Security authority (EFSA) recommendations:

1-<https://www.efsa.europa.eu/it/efsajournal/pub/2557>

2-<https://www.efsa.europa.eu/it/efsajournal/pub/1462>

3-<https://www.efsa.europa.eu/it/efsajournal/pub/1461>

Table 2. Exclusion diets and related risks in Inflammatory Bowel Disease

Exclusion diets	Not allowed foods	Risk*
Ovo-lacto-vegetarian	Meat, Fish	None
Lactose free (reduced)	Animal milk /products high in lactose	None, if dairy products low in lactose are not avoided
Vegan	All foods from animals	Low vitamin A, B12, D, Zinc, low protein intake
Paleolithic diet	Potatoes, legumes, cereal grain, domesticated meat, all dairy products, juices, soft drinks, refined sugar	Increased fats intake Hypocalcemia
Spec. carbohydrate diet	Mono-, disaccharides, potatoes, Yams, legumes, canned products, cereal grains, milks, sweets, margarine, beer	Reduced caloric intake, B and D Hypovitaminosis, hypocalcemia and hyposideremia
Low FODMAP diet	Mono-, di- oligosaccharides, fiber, wheat, rye, many fruits and vegetables, milk	If long-term, reduction of Calcium, Folate, Thiamin, Vitamin B6
CD exclusion diet (50% polymeric formula)	Dairy products except the allowed formula, margarine, gluten, processed and smoked meat and fish, canned products, yeast, soy, potato or corn flours, soft drinks, fruit juices, alcoholic beverages, coffee, chocolates, cakes, cookies, gums.	None
IgG4 based exclusion	Individual, mostly dairy, egg, pork, beef	Depending on the excluded foods

*Possible nutritional risks in children undergoing diets without nutritional advise.